BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11303890)

  • 1. Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin.
    de Keizer B; Koppeschaar HP; Zelissen PM; Lips CJ; van Rijk PP; van Dijk A; de Klerk JM
    Eur J Nucl Med; 2001 Feb; 28(2):198-202. PubMed ID: 11303890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study.
    Koh JM; Kim ES; Ryu JS; Hong SJ; Kim WB; Shong YK
    Clin Endocrinol (Oxf); 2003 Apr; 58(4):421-7. PubMed ID: 12641624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
    de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer.
    Lima N; Cavaliere H; Tomimori E; Knobel M; Medeiros-Neto G
    J Endocrinol Invest; 2002 Feb; 25(2):110-5. PubMed ID: 11929080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follow-up of differentiated thyroid carcinoma.
    Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
    Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
    Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin.
    van Tol KM; Jager PL; de Vries EG; Piers DA; Boezen HM; Sluiter WJ; Dullaart RP; Links TP
    Eur J Endocrinol; 2003 Jun; 148(6):589-96. PubMed ID: 12773129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients.
    Pacini F; Agate L; Elisei R; Capezzone M; Ceccarelli C; Lippi F; Molinaro E; Pinchera A
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4092-7. PubMed ID: 11549631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy analysis of (131)I therapy and predictive value of preablation stimulated thyroglobulin for lung metastases from differentiated thyroid cancer.
    Wu S; Wang H
    Ann Endocrinol (Paris); 2013 Feb; 74(1):40-4. PubMed ID: 23337017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results?
    Ma C; Xie J; Kuang A
    J Nucl Med; 2005 Jul; 46(7):1164-70. PubMed ID: 16000286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
    Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment.
    Pace L; Klain M; Albanese C; Salvatore B; Storto G; Soricelli A; Salvatore M
    Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):179-83. PubMed ID: 16205897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
    Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
    J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid lobe ablation with radioactive iodine as an alternative to completion thyroidectomy after hemithyroidectomy in patients with follicular thyroid carcinoma: long-term follow-up.
    Barbesino G; Goldfarb M; Parangi S; Yang J; Ross DS; Daniels GH
    Thyroid; 2012 Apr; 22(4):369-76. PubMed ID: 22385290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer.
    Ozata M; Suzuki S; Miyamoto T; Liu RT; Fierro-Renoy F; DeGroot LJ
    J Clin Endocrinol Metab; 1994 Jul; 79(1):98-105. PubMed ID: 8027262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.
    Siddiqi A; Foley RR; Britton KE; Sibtain A; Plowman PN; Grossman AB; Monson JP; Besser GM
    Clin Endocrinol (Oxf); 2001 Oct; 55(4):515-21. PubMed ID: 11678835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma.
    Pluijmen MJ; Eustatia-Rutten C; Goslings BM; Stokkel MP; Arias AM; Diamant M; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2003 Apr; 58(4):428-35. PubMed ID: 12641625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Embolization in combination with radioiodine therapy for bone metastases from differentiated thyroid carcinoma.
    Van Tol KM; Hew JM; Jager PL; Vermey A; Dullaart RP; Links TP
    Clin Endocrinol (Oxf); 2000 May; 52(5):653-9. PubMed ID: 10792347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.